MA53706A - Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne - Google Patents

Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne

Info

Publication number
MA53706A
MA53706A MA053706A MA53706A MA53706A MA 53706 A MA53706 A MA 53706A MA 053706 A MA053706 A MA 053706A MA 53706 A MA53706 A MA 53706A MA 53706 A MA53706 A MA 53706A
Authority
MA
Morocco
Prior art keywords
treatment
bacterial infection
indane derivatives
indane
derivatives
Prior art date
Application number
MA053706A
Other languages
English (en)
Inventor
Lilha Beyria
Toby Jonathan Blench
David Edward Clark
Andrew Peter Cridland
David Thomas Davies
Richard Leonard Elliott
Martin Everett
Simon Leiris
Thomas David Pallin
Nicolas Sprynski
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290106.6A external-priority patent/EP3628666A1/fr
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of MA53706A publication Critical patent/MA53706A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053706A 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne MA53706A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290106.6A EP3628666A1 (fr) 2018-09-25 2018-09-25 Dérivés d'indane pour le traitement des infections bactériennes
EP18290104 2018-09-26
EP18197365 2018-09-27

Publications (1)

Publication Number Publication Date
MA53706A true MA53706A (fr) 2021-12-29

Family

ID=67439236

Family Applications (2)

Application Number Title Priority Date Filing Date
MA053707A MA53707A (fr) 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
MA053706A MA53706A (fr) 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA053707A MA53707A (fr) 2018-09-25 2019-07-25 Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne

Country Status (14)

Country Link
US (2) US20210347748A1 (fr)
EP (2) EP3856729A1 (fr)
JP (2) JP7429992B2 (fr)
KR (2) KR20210087025A (fr)
CN (2) CN113166084A (fr)
AU (2) AU2019349438A1 (fr)
BR (2) BR112021005532A2 (fr)
CA (2) CA3113689A1 (fr)
CL (2) CL2021000729A1 (fr)
IL (2) IL281780A (fr)
MA (2) MA53707A (fr)
MX (2) MX2021003485A (fr)
SG (2) SG11202102790PA (fr)
WO (2) WO2020064174A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166084A (zh) * 2018-09-25 2021-07-23 安塔比奥公司 用于治疗细菌感染的茚满衍生物
WO2021191240A1 (fr) * 2020-03-24 2021-09-30 Antabio Sas Polythérapie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JP3126541B2 (ja) * 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
JPH0782259A (ja) * 1993-09-14 1995-03-28 Senju Pharmaceut Co Ltd スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
CA2579221A1 (fr) 2004-09-08 2006-03-16 Merck & Co., Inc. Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
FR2883876B1 (fr) 2005-03-30 2007-05-04 Servier Lab Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5028413B2 (ja) 2005-05-25 2012-09-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラン−ジオキサン誘導体類、および液晶媒体中におけるそれの使用
MY154462A (en) 2007-06-05 2015-06-30 Sanofi Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
EP2141164A1 (fr) * 2008-07-01 2010-01-06 Mutabilis Nouveaux dérivés 1,2,4-triazine et leurs applications biologiques
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP2925137A1 (fr) * 2012-11-30 2015-10-07 Bayer CropScience AG Mélange fongicide ou pesticide binaire
GB201704476D0 (en) * 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
CN113166084A (zh) 2018-09-25 2021-07-23 安塔比奥公司 用于治疗细菌感染的茚满衍生物

Also Published As

Publication number Publication date
JP7429992B2 (ja) 2024-02-09
BR112021005532A2 (pt) 2021-06-29
CL2021000729A1 (es) 2021-11-05
MA53707A (fr) 2021-12-29
BR112021005651A2 (pt) 2021-06-22
SG11202102791SA (en) 2021-04-29
MX2021003485A (es) 2021-09-10
US20210347748A1 (en) 2021-11-11
CA3113689A1 (fr) 2020-04-02
CN113166085B (zh) 2024-04-09
JP7429993B2 (ja) 2024-02-09
CN113166084A (zh) 2021-07-23
KR20210087448A (ko) 2021-07-12
JP2022502486A (ja) 2022-01-11
WO2020064173A1 (fr) 2020-04-02
AU2019351551A1 (en) 2021-04-15
WO2020064174A1 (fr) 2020-04-02
US20220112169A1 (en) 2022-04-14
KR20210087025A (ko) 2021-07-09
JP2022502485A (ja) 2022-01-11
EP3856730A1 (fr) 2021-08-04
CL2021000731A1 (es) 2021-11-05
EP3856729A1 (fr) 2021-08-04
SG11202102790PA (en) 2021-04-29
IL281780A (en) 2021-05-31
CN113166085A (zh) 2021-07-23
MX2021003498A (es) 2021-09-10
CA3113697A1 (fr) 2020-04-02
IL281770A (en) 2021-05-31
AU2019349438A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
MA49760A (fr) Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA50673A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA44676A (fr) Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA40221A (fr) Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA43811A (fr) Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
MA50233A (fr) Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA53706A (fr) Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne
MA52137A (fr) Méthodes de traitement de l'amylose ttr à l'aide d'ag10
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA54290A (fr) Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome